Pfizer has reduced the number of drugs in its pipeline according to a report in InPharm. The project is of course necessitated by its acquisition of Wyeth as the company takes a hard look at which drugs will provide the greatest return - and help to replace revenue soon to be lost via patent expirations.
Pfizer says it will cut 31 programs overall. Of the 31 programs to be cut, 15 are in phase I. Pfizer will still have 26 programs in phase III and 9 in registration. It also has 27 products that are biologics and another 4 vaccines in development.
As announced earlier this year, Pfizer will place more emphasis on rare, orphan and neglected diseases - including new drugs for onchocerciasis (river blindness) and the fungal infection aspergillosis - often seen in immuno-compromised patients.
Posted by Bruce Lehr September 28th 2010.